Septerna, Inc. Files 8-K: Board & Executive Compensation Updates
Ticker: SEPN · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1984086
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
TL;DR
Septerna's 8-K: Board shakeup and exec pay changes filed Dec 6.
AI Summary
On December 6, 2024, Septerna, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes information regarding the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its key executives. This report also covers Regulation FD disclosures and financial statements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect future business operations and financial performance.
Key Players & Entities
- Septerna, Inc. (company) — Registrant
- December 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 250 East Grand Avenue, Suite 65, South San Francisco, CA 94080 (address) — Principal Executive Offices
- 650-338-3533 (phone_number) — Business Phone
FAQ
What specific items are covered in Septerna, Inc.'s 8-K filing dated December 6, 2024?
The 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD disclosures, and financial statements and exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 6, 2024.
What is Septerna, Inc.'s state of incorporation and principal executive office address?
Septerna, Inc. is incorporated in Delaware and its principal executive offices are located at 250 East Grand Avenue, Suite 65, South San Francisco, CA 94080.
What is the SIC code for Septerna, Inc.?
The Standard Industrial Classification (SIC) code for Septerna, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the phone number listed for Septerna, Inc.'s principal executive offices?
The phone number listed for Septerna, Inc.'s principal executive offices is (650) 338-3533.
Filing Stats: 2,020 words · 8 min read · ~7 pages · Grade level 11.9 · Accepted 2025-01-06 07:14:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share SEPN The Nasdaq
- $485,000 — r. Labrucherie an annual base salary of $485,000. Mr. Labrucherie is also eligible to ea
Filing Documents
- d753888d8k.htm (8-K) — 36KB
- d753888dex101.htm (EX-10.1) — 31KB
- d753888dex991.htm (EX-99.1) — 6KB
- g753888g59m81.jpg (GRAPHIC) — 3KB
- 0001193125-25-001834.txt ( ) — 219KB
- sepn-20241206.xsd (EX-101.SCH) — 2KB
- sepn-20241206_lab.xml (EX-101.LAB) — 18KB
- sepn-20241206_pre.xml (EX-101.PRE) — 11KB
- d753888d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 SEPTERNA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-42382 84-3891440 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Septerna, Inc. 250 East Grand Avenue South San Francisco , CA 94080 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: ( 650 ) 338-3533 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share SEPN The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer On December 23, 2024, the Board of Directors (the "Board") of Septerna, Inc. (the "Company") appointed Gil M. Labrucherie as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company, in each case, effective as of January 6, 2025. Mr. Labrucherie, age 53, has over 25 years of senior leadership experience in the biotechnology sector. Prior to joining the Company, from July 2022 to November 2022 and from September 2023 to January 2025, Mr. Labrucherie served as the Chief Financial Officer of Acelyrin, Inc., a publicly traded late-stage clinical biopharmaceutical company, where he also served as the Chief Business Officer from May 2024 to January 2025. Mr. Labrucherie is currently a sole trustee of the Bloom Trust, a closely held family office with commercial real estate assets and operations. He previously served as the Chief Financial Officer of Nektar Therapeutics, a publicly traded development stage biopharmaceutical company, from June 2016 to June 2022, and also held the position of Chief Operating Officer from November 2019 to June 2022. Prior to serving as Chief Operating Officer and Chief Financial Officer of Nektar Therapeutics, he was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Mr. Labrucherie served in numerous executive leadership roles at high growth technology companies, where he was responsible for global corporate alliance and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Labrucherie has served as a member of the board of directors of Rezolute, Inc., a publicly traded late-stage biopharmaceutical company, since November 2019, and previously served as a director of Valinor Pharma LLC, a private company focused on innovative commercialization of medicines from May 2023 until its acquisition by Grnenthal in July 2024. Mr. Labrucherie received his J.D. from the University of California Berkeley School of Law, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a CFA charterholder and a member of the State Bar of California. In connection with Mr. Labrucherie's appointment as the Chief Financial Officer, the Company entered into an offer letter with him (the "Offer Letter"), pursuant to which the Company has agreed to pay Mr. Labrucherie an annual base salary of $485,000. Mr. Labrucherie is also eligible to earn an annual target bonus of 40% of his annual base salary. During Mr. Labrucherie's employment, he will be eligible to participate in the Company's Executive Severance Plan